Cogent BiosciencesCOGT
About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Employees: 205
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
37% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 46
14% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]
7% more funds holding
Funds holding: 161 [Q3] → 173 (+12) [Q4]
1.14% less ownership
Funds ownership: 111.31% [Q3] → 110.17% (-1.14%) [Q4]
28% less capital invested
Capital invested by funds: $1.32B [Q3] → $949M (-$367M) [Q4]
65% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $3.41M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Scotiabank Louise Chen 27% 1-year accuracy 32 / 118 met price target | 239%upside $17 | Sector Outperform Initiated | 7 Mar 2025 |
Baird Joel Beatty 29% 1-year accuracy 11 / 38 met price target | 59%upside $8 | Neutral Maintained | 27 Feb 2025 |
Financial journalist opinion
